MacroGenics, Inc. (MGNX)
NASDAQ · Manufacturing · Pharmaceutical preparations
MGNX price, last 12 months
Key stats
- Previous close
- $1.97
- Open
- $1.99
- Day range
- $1.90 – $2.06
- 52-week range
- $1.32 – $5.08
- Volume
- 932.9K
- Avg volume (20 days)
- 1.2M
- Market cap
- $140.6M
Performance
Technicals and fundamentals
About MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $140.6M